Difference between revisions of "User:Bailey.Glen"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
Line 20: Line 20:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Columnar_cell_lesions,_including_flat_epithelial_atypia_|Columnar cell lesions, including flat epithelial atypia ]]
+
|-
 +
|[[BRST5:Columnar_cell_lesions,_including_flat_epithelial_atypia_|Columnar cell lesions, including flat epithelial atypia ]]
 
|Disease
 
|Disease
 
|
 
|
Line 30: Line 31:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Atypical_ductal_hyperplasia|Atypical ductal hyperplasia]]
+
|-
 +
|[[BRST5:Atypical_ductal_hyperplasia|Atypical ductal hyperplasia]]
 
|Disease
 
|Disease
 
|
 
|
Line 40: Line 42:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Sclerosing_adenosis|Sclerosing adenosis]]
+
|-
 +
|[[BRST5:Sclerosing_adenosis|Sclerosing adenosis]]
 
|Disease
 
|Disease
 
|
 
|
Line 50: Line 53:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Apocrine_adenosis_and_adenoma|Apocrine adenosis and adenoma]]
+
|-
 +
|[[BRST5:Apocrine_adenosis_and_adenoma|Apocrine adenosis and adenoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 60: Line 64:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Microglandular_adenosis_|Microglandular adenosis ]]
+
|-
 +
|[[BRST5:Microglandular_adenosis_|Microglandular adenosis ]]
 
|Disease
 
|Disease
 
|
 
|
Line 70: Line 75:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Radial_scar_/_complex_sclerosing_lesion_|Radial scar / complex sclerosing lesion ]]
+
|-
 +
|[[BRST5:Radial_scar_/_complex_sclerosing_lesion_|Radial scar / complex sclerosing lesion ]]
 
|Disease
 
|Disease
 
|
 
|
Line 80: Line 86:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Tubular_adenoma_|Tubular adenoma ]]
+
|-
 +
|[[BRST5:Tubular_adenoma_|Tubular adenoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 90: Line 97:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Lactating_adenoma_|Lactating adenoma ]]
+
|-
 +
|[[BRST5:Lactating_adenoma_|Lactating adenoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 100: Line 108:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Ductal_adenoma|Ductal adenoma]]
+
|-
 +
|[[BRST5:Ductal_adenoma|Ductal adenoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 110: Line 119:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Pleomorphic_adenoma|Pleomorphic adenoma]]
+
|-
 +
|[[BRST5:Pleomorphic_adenoma|Pleomorphic adenoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 120: Line 130:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]
+
|-
 +
|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]
 
|Disease
 
|Disease
 
|
 
|
Line 130: Line 141:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Malignant_adenomyoepithelioma|Malignant adenomyoepithelioma]]
+
|-
 +
|[[BRST5:Malignant_adenomyoepithelioma|Malignant adenomyoepithelioma]]
 
|Disease
 
|Disease
 
|
 
|
Line 140: Line 152:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Intraductal_papilloma|Intraductal papilloma]]
+
|-
 +
|[[BRST5:Intraductal_papilloma|Intraductal papilloma]]
 
|Disease
 
|Disease
 
|
 
|
Line 150: Line 163:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Papillary_ductal_carcinoma_in_situ|Papillary ductal carcinoma in situ]]
+
|-
 +
|[[BRST5:Papillary_ductal_carcinoma_in_situ|Papillary ductal carcinoma in situ]]
 
|Disease
 
|Disease
 
|
 
|
Line 160: Line 174:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Encapsulated_papillary_carcinoma|Encapsulated papillary carcinoma]]
+
|-
 +
|[[BRST5:Encapsulated_papillary_carcinoma|Encapsulated papillary carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 170: Line 185:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Solid_papillary_carcinoma_(in_situ_and_invasive)|Solid papillary carcinoma (in situ and invasive)]]
+
|-
 +
|[[BRST5:Solid_papillary_carcinoma_(in_situ_and_invasive)|Solid papillary carcinoma (in situ and invasive)]]
 
|Disease
 
|Disease
 
|
 
|
Line 180: Line 196:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Invasive_papillary_carcinoma|Invasive papillary carcinoma]]
+
|-
 +
|[[BRST5:Invasive_papillary_carcinoma|Invasive papillary carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 190: Line 207:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Atypical_lobular_hyperplasia_|Atypical lobular hyperplasia ]]
+
|-
 +
|[[BRST5:Atypical_lobular_hyperplasia_|Atypical lobular hyperplasia ]]
 
|Disease
 
|Disease
 
|
 
|
Line 200: Line 218:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Lobular_carcinoma_in_situ|Lobular carcinoma in situ]]
+
|-
 +
|[[BRST5:Lobular_carcinoma_in_situ|Lobular carcinoma in situ]]
 
|Disease
 
|Disease
 
|
 
|
Line 210: Line 229:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Ductal_carcinoma_in_situ_|Ductal carcinoma in situ ]]
+
|-
 +
|[[BRST5:Ductal_carcinoma_in_situ_|Ductal carcinoma in situ ]]
 
|Disease
 
|Disease
 
|
 
|
Line 220: Line 240:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Invasive_breast_carcinoma:_General_overview|Invasive breast carcinoma: General overview]]
+
|-
 +
|[[BRST5:Invasive_breast_carcinoma:_General_overview|Invasive breast carcinoma: General overview]]
 
|Disease
 
|Disease
 
|
 
|
Line 230: Line 251:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Invasive_breast_carcinoma_of_no_special_type|Invasive breast carcinoma of no special type]]
+
|-
 +
|[[BRST5:Invasive_breast_carcinoma_of_no_special_type|Invasive breast carcinoma of no special type]]
 
|Disease
 
|Disease
 
|
 
|
Line 240: Line 262:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Microinvasive_carcinoma|Microinvasive carcinoma]]
+
|-
 +
|[[BRST5:Microinvasive_carcinoma|Microinvasive carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 250: Line 273:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Invasive_lobular_carcinoma_|Invasive lobular carcinoma ]]
+
|-
 +
|[[BRST5:Invasive_lobular_carcinoma_|Invasive lobular carcinoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 260: Line 284:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Tubular_carcinoma|Tubular carcinoma]]
+
|-
 +
|[[BRST5:Tubular_carcinoma|Tubular carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 270: Line 295:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Cribriform_carcinoma|Cribriform carcinoma]]
+
|-
 +
|[[BRST5:Cribriform_carcinoma|Cribriform carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 280: Line 306:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Mucinous_carcinoma|Mucinous carcinoma]]
+
|-
 +
|[[BRST5:Mucinous_carcinoma|Mucinous carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 290: Line 317:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Mucinous_cystadenocarcinoma|Mucinous cystadenocarcinoma]]
+
|-
 +
|[[BRST5:Mucinous_cystadenocarcinoma|Mucinous cystadenocarcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 300: Line 328:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Invasive_micropapillary_carcinoma|Invasive micropapillary carcinoma]]
+
|-
 +
|[[BRST5:Invasive_micropapillary_carcinoma|Invasive micropapillary carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 310: Line 339:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Carcinoma_with_apocrine_differentiation|Carcinoma with apocrine differentiation]]
+
|-
 +
|[[BRST5:Carcinoma_with_apocrine_differentiation|Carcinoma with apocrine differentiation]]
 
|Disease
 
|Disease
 
|
 
|
Line 320: Line 350:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Metaplastic_carcinoma|Metaplastic carcinoma]]
+
|-
 +
|[[BRST5:Metaplastic_carcinoma|Metaplastic carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 330: Line 361:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Acinic_cell_carcinoma|Acinic cell carcinoma]]
+
|-
 +
|[[BRST5:Acinic_cell_carcinoma|Acinic cell carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 340: Line 372:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Adenoid_cystic_carcinoma|Adenoid cystic carcinoma]]
+
|-
 +
|[[BRST5:Adenoid_cystic_carcinoma|Adenoid cystic carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 350: Line 383:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Secretory_carcinoma_|Secretory carcinoma ]]
+
|-
 +
|[[BRST5:Secretory_carcinoma_|Secretory carcinoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 360: Line 394:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Mucoepidermoid_carcinoma|Mucoepidermoid carcinoma]]
+
|-
 +
|[[BRST5:Mucoepidermoid_carcinoma|Mucoepidermoid carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 370: Line 405:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Polymorphous_adenocarcinoma|Polymorphous adenocarcinoma]]
+
|-
 +
|[[BRST5:Polymorphous_adenocarcinoma|Polymorphous adenocarcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 380: Line 416:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Tall_cell_carcinoma_with_reversed_polarity|Tall cell carcinoma with reversed polarity]]
+
|-
 +
|[[BRST5:Tall_cell_carcinoma_with_reversed_polarity|Tall cell carcinoma with reversed polarity]]
 
|Disease
 
|Disease
 
|
 
|
Line 390: Line 427:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Neuroendocrine_tumour|Neuroendocrine tumour]]
+
|-
 +
|[[BRST5:Neuroendocrine_tumour|Neuroendocrine tumour]]
 
|Disease
 
|Disease
 
|
 
|
Line 400: Line 438:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Neuroendocrine_carcinoma|Neuroendocrine carcinoma]]
+
|-
 +
|[[BRST5:Neuroendocrine_carcinoma|Neuroendocrine carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 410: Line 449:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Hamartoma_|Hamartoma ]]
+
|-
 +
|[[BRST5:Hamartoma_|Hamartoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 420: Line 460:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Fibroadenoma_|Fibroadenoma ]]
+
|-
 +
|[[BRST5:Fibroadenoma_|Fibroadenoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 430: Line 471:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Phyllodes_tumour_|Phyllodes tumour ]]
+
|-
 +
|[[BRST5:Phyllodes_tumour_|Phyllodes tumour ]]
 
|Disease
 
|Disease
 
|
 
|
Line 440: Line 482:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Syringomatous_tumour_|Syringomatous tumour ]]
+
|-
 +
|[[BRST5:Syringomatous_tumour_|Syringomatous tumour ]]
 
|Disease
 
|Disease
 
|
 
|
Line 450: Line 493:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Nipple_adenoma_|Nipple adenoma ]]
+
|-
 +
|[[BRST5:Nipple_adenoma_|Nipple adenoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 460: Line 504:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Paget_disease_of_the_breast|Paget disease of the breast]]
+
|-
 +
|[[BRST5:Paget_disease_of_the_breast|Paget disease of the breast]]
 
|Disease
 
|Disease
 
|
 
|
Line 470: Line 515:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Haemangioma|Haemangioma]]
+
|-
 +
|[[BRST5:Haemangioma|Haemangioma]]
 
|Disease
 
|Disease
 
|
 
|
Line 480: Line 526:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Angiomatosis|Angiomatosis]]
+
|-
 +
|[[BRST5:Angiomatosis|Angiomatosis]]
 
|Disease
 
|Disease
 
|
 
|
Line 490: Line 537:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Atypical_vascular_lesions_|Atypical vascular lesions ]]
+
|-
 +
|[[BRST5:Atypical_vascular_lesions_|Atypical vascular lesions ]]
 
|Disease
 
|Disease
 
|
 
|
Line 500: Line 548:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Postradiation_angiosarcoma_of_the_breast|Postradiation angiosarcoma of the breast]]
+
|-
 +
|[[BRST5:Postradiation_angiosarcoma_of_the_breast|Postradiation angiosarcoma of the breast]]
 
|Disease
 
|Disease
 
|
 
|
Line 510: Line 559:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Primary_angiosarcoma_of_the_breast|Primary angiosarcoma of the breast]]
+
|-
 +
|[[BRST5:Primary_angiosarcoma_of_the_breast|Primary angiosarcoma of the breast]]
 
|Disease
 
|Disease
 
|
 
|
Line 520: Line 570:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Nodular_fasciitis|Nodular fasciitis]]
+
|-
 +
|[[BRST5:Nodular_fasciitis|Nodular fasciitis]]
 
|Disease
 
|Disease
 
|
 
|
Line 530: Line 581:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Myofibroblastoma|Myofibroblastoma]]
+
|-
 +
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 540: Line 592:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Desmoid_fibromatosis_|Desmoid fibromatosis ]]
+
|-
 +
|[[BRST5:Desmoid_fibromatosis_|Desmoid fibromatosis ]]
 
|Disease
 
|Disease
 
|
 
|
Line 550: Line 603:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Inflammatory_myofibroblastic_tumour_|Inflammatory myofibroblastic tumour ]]
+
|-
 +
|[[BRST5:Inflammatory_myofibroblastic_tumour_|Inflammatory myofibroblastic tumour ]]
 
|Disease
 
|Disease
 
|
 
|
Line 560: Line 614:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Schwannoma_|Schwannoma ]]
+
|-
 +
|[[BRST5:Schwannoma_|Schwannoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 570: Line 625:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Neurofibroma_|Neurofibroma ]]
+
|-
 +
|[[BRST5:Neurofibroma_|Neurofibroma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 580: Line 636:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Granular_cell_tumour|Granular cell tumour]]
+
|-
 +
|[[BRST5:Granular_cell_tumour|Granular cell tumour]]
 
|Disease
 
|Disease
 
|
 
|
Line 590: Line 647:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Leiomyoma|Leiomyoma]]
+
|-
 +
|[[BRST5:Leiomyoma|Leiomyoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 600: Line 658:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Leiomyosarcoma_|Leiomyosarcoma ]]
+
|-
 +
|[[BRST5:Leiomyosarcoma_|Leiomyosarcoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 610: Line 669:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Lipoma_|Lipoma ]]
+
|-
 +
|[[BRST5:Lipoma_|Lipoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 620: Line 680:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Angiolipoma_|Angiolipoma ]]
+
|-
 +
|[[BRST5:Angiolipoma_|Angiolipoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 630: Line 691:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Liposarcoma_|Liposarcoma ]]
+
|-
 +
|[[BRST5:Liposarcoma_|Liposarcoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 640: Line 702:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Pseudoangiomatous_stromal_hyperplasia|Pseudoangiomatous stromal hyperplasia]]
+
|-
 +
|[[BRST5:Pseudoangiomatous_stromal_hyperplasia|Pseudoangiomatous stromal hyperplasia]]
 
|Disease
 
|Disease
 
|
 
|
Line 650: Line 713:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue_(MALT_lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]
+
|-
 +
|[[BRST5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue_(MALT_lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]
 
|Disease
 
|Disease
 
|
 
|
Line 660: Line 724:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Follicular_lymphoma_|Follicular lymphoma ]]
+
|-
 +
|[[BRST5:Follicular_lymphoma_|Follicular lymphoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 670: Line 735:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Diffuse_large_B-cell_lymphoma_|Diffuse large B-cell lymphoma ]]
+
|-
 +
|[[BRST5:Diffuse_large_B-cell_lymphoma_|Diffuse large B-cell lymphoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 680: Line 746:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Burkitt_lymphoma|Burkitt lymphoma]]
+
|-
 +
|[[BRST5:Burkitt_lymphoma|Burkitt lymphoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 690: Line 757:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Breast_implant-associated_anaplastic_large_cell_lymphoma_|Breast implant-associated anaplastic large cell lymphoma ]]
+
|-
 +
|[[BRST5:Breast_implant-associated_anaplastic_large_cell_lymphoma_|Breast implant-associated anaplastic large cell lymphoma ]]
 
|Disease
 
|Disease
 
|
 
|
Line 700: Line 768:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Gynaecomastia|Gynaecomastia]]
+
|-
 +
|[[BRST5:Gynaecomastia|Gynaecomastia]]
 
|Disease
 
|Disease
 
|
 
|
Line 710: Line 779:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Carcinoma_in_situ|Carcinoma in situ]]
+
|-
 +
|[[BRST5:Carcinoma_in_situ|Carcinoma in situ]]
 
|Disease
 
|Disease
 
|
 
|
Line 720: Line 790:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Invasive_carcinoma|Invasive carcinoma]]
+
|-
 +
|[[BRST5:Invasive_carcinoma|Invasive carcinoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 730: Line 801:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Metastases_to_the_breast|Metastases to the breast]]
+
|-
 +
|[[BRST5:Metastases_to_the_breast|Metastases to the breast]]
 
|Disease
 
|Disease
 
|
 
|
Line 740: Line 812:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]
+
|-
 +
|[[BRST5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]
 
|Disease
 
|Disease
 
|
 
|
Line 750: Line 823:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Cowden_syndrome|Cowden syndrome]]
+
|-
 +
|[[BRST5:Cowden_syndrome|Cowden syndrome]]
 
|Disease
 
|Disease
 
|
 
|
Line 760: Line 834:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]
+
|-
 +
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]
 
|Disease
 
|Disease
 
|
 
|
Line 770: Line 845:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Li-Fraumeni_syndrome,_TP53-associated|Li-Fraumeni syndrome, TP53-associated]]
+
|-
 +
|[[BRST5:Li-Fraumeni_syndrome,_TP53-associated|Li-Fraumeni syndrome, TP53-associated]]
 
|Disease
 
|Disease
 
|
 
|
Line 780: Line 856:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Li-Fraumeni_syndrome,_CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]
+
|-
 +
|[[BRST5:Li-Fraumeni_syndrome,_CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]
 
|Disease
 
|Disease
 
|
 
|
Line 790: Line 867:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:CDH1-associated_breast_cancer|CDH1-associated breast cancer]]
+
|-
 +
|[[BRST5:CDH1-associated_breast_cancer|CDH1-associated breast cancer]]
 
|Disease
 
|Disease
 
|
 
|
Line 800: Line 878:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:PALB2-associated_cancers|PALB2-associated cancers]]
+
|-
 +
|[[BRST5:PALB2-associated_cancers|PALB2-associated cancers]]
 
|Disease
 
|Disease
 
|
 
|
Line 810: Line 889:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]]
+
|-
 +
|[[BRST5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]]
 
|Disease
 
|Disease
 
|
 
|
Line 820: Line 900:
 
|
 
|
 
|
 
|
−
|-|[[BRST5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
+
|-
 +
|[[BRST5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
 
|Disease
 
|Disease
 
|
 
|

Revision as of 12:19, 26 January 2024

WHO Classification of Tumours of the Central Nervous System (5th Edition) Content
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Disease
Columnar cell lesions, including flat epithelial atypia Disease
Atypical ductal hyperplasia Disease
Sclerosing adenosis Disease
Apocrine adenosis and adenoma Disease
Microglandular adenosis Disease
Radial scar / complex sclerosing lesion Disease
Tubular adenoma Disease
Lactating adenoma Disease
Ductal adenoma Disease
Pleomorphic adenoma Disease
Adenomyoepithelioma Disease
Malignant adenomyoepithelioma Disease
Intraductal papilloma Disease
Papillary ductal carcinoma in situ Disease
Encapsulated papillary carcinoma Disease
Solid papillary carcinoma (in situ and invasive) Disease
Invasive papillary carcinoma Disease
Atypical lobular hyperplasia Disease
Lobular carcinoma in situ Disease
Ductal carcinoma in situ Disease
Invasive breast carcinoma: General overview Disease
Invasive breast carcinoma of no special type Disease
Microinvasive carcinoma Disease
Invasive lobular carcinoma Disease
Tubular carcinoma Disease
Cribriform carcinoma Disease
Mucinous carcinoma Disease
Mucinous cystadenocarcinoma Disease
Invasive micropapillary carcinoma Disease
Carcinoma with apocrine differentiation Disease
Metaplastic carcinoma Disease
Acinic cell carcinoma Disease
Adenoid cystic carcinoma Disease
Secretory carcinoma Disease
Mucoepidermoid carcinoma Disease
Polymorphous adenocarcinoma Disease
Tall cell carcinoma with reversed polarity Disease
Neuroendocrine tumour Disease
Neuroendocrine carcinoma Disease
Hamartoma Disease
Fibroadenoma Disease
Phyllodes tumour Disease
Syringomatous tumour Disease
Nipple adenoma Disease
Paget disease of the breast Disease
Haemangioma Disease
Angiomatosis Disease
Atypical vascular lesions Disease
Postradiation angiosarcoma of the breast Disease
Primary angiosarcoma of the breast Disease
Nodular fasciitis Disease
Myofibroblastoma Disease
Desmoid fibromatosis Disease
Inflammatory myofibroblastic tumour Disease
Schwannoma Disease
Neurofibroma Disease
Granular cell tumour Disease
Leiomyoma Disease
Leiomyosarcoma Disease
Lipoma Disease
Angiolipoma Disease
Liposarcoma Disease
Pseudoangiomatous stromal hyperplasia Disease
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Disease
Follicular lymphoma Disease
Diffuse large B-cell lymphoma Disease
Burkitt lymphoma Disease
Breast implant-associated anaplastic large cell lymphoma Disease
Gynaecomastia Disease
Carcinoma in situ Disease
Invasive carcinoma Disease
Metastases to the breast Disease
BRCA1/2-associated hereditary breast and ovarian cancer syndrome Disease
Cowden syndrome Disease
Ataxia-telangiectasia Disease
Li-Fraumeni syndrome, TP53-associated Disease
Li-Fraumeni syndrome, CHEK2-associated Disease
CDH1-associated breast cancer Disease
PALB2-associated cancers Disease
Peutz-Jeghers syndrome Disease
Neurofibromatosis type 1 Disease
Retrieved from "https://ccga.io/index.php?title=User:Bailey.Glen&oldid=14122"